Phathom Pharmaceuticals/PHAT

$10.15

2.42%
-
1D1W1MYTD1YMAX

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Ticker

PHAT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Terrie Curran

Employees

112

Headquarters

Florham park, United States

PHAT Metrics

BasicAdvanced
$606.88M
Market cap
-
P/E ratio
-$3.83
EPS
0.62
Beta
-
Dividend rate

What the Analysts think about PHAT

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
123.74% upside
High $28.00
Low $10.00
$10.15
Current price
$22.71
Average price target

PHAT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-43.2M
5.62%
Profit margin
0%
-

PHAT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 14.74%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$1.33
-$0.89
-$0.84
-$0.76
-
Expected
-$1.35
-$1.26
-$0.98
-$0.89
-$1.08
Surprise
-1.6%
-29.39%
-14.16%
-14.74%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Phathom Pharmaceuticals stock

Buy or sell Phathom Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing